Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Faron Pharmaceuticals (FARN) Share Price

Price 41.50p on 09-07-2026 at 16:30:00
Change 0.50p 1.22%
Buy 43.00p
Sell 40.00p
Last Trade: Buy 20,000.00 at 42.20p
Day's Volume: 29,176
Last Close: 41.50p
Open: 41.00p
ISIN: FI4000153309
Day's Range 41.00p - 41.50p
52wk Range: 38.70p - 240.00p
Market Capitalisation: £84.20m
VWAP: 41.7855p
Shares in Issue: 202.88m

Faron Pharmaceuticals (FARN) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 20,000 42.20p Ordinary
16:25:16 - 09-Jul-26
Sell* 287 40.02p Ordinary
14:00:28 - 09-Jul-26
Sell* 717 40.10p Ordinary
13:59:20 - 09-Jul-26
Sell* 172 40.10p Ordinary
13:54:29 - 09-Jul-26
Sell* 8,000 40.9999p Ordinary
08:04:39 - 09-Jul-26
Buy* 25,000 41.20p Ordinary
16:38:35 - 08-Jul-26
Sell* 457 40.10p Ordinary
15:17:11 - 08-Jul-26
Sell* 767 40.02p Ordinary
14:26:49 - 08-Jul-26
Buy* 7 42.00p SI Trade
10:52:29 - 08-Jul-26
Buy* 357 41.90p Ordinary
09:01:45 - 08-Jul-26
See more Faron Pharmaceuticals trades

Faron Pharmaceuticals (FARN) Share Price History

Time period:
to
Date Open High Low Close Volume
9th Jul 2026 (Thu) 41.00 41.50 41.00 41.50 29,176
8th Jul 2026 (Wed) 41.00 41.00 41.00 41.00 26,588
7th Jul 2026 (Tue) 41.00 41.00 41.00 41.00 32,685
6th Jul 2026 (Mon) 42.00 42.00 41.00 41.00 50,250
3rd Jul 2026 (Fri) 41.00 42.00 41.00 42.00 65,101
2nd Jul 2026 (Thu) 41.00 41.00 41.00 41.00 559
1st Jul 2026 (Wed) 41.00 41.00 41.00 41.00 37,577
30th Jun 2026 (Tue) 41.00 41.00 41.00 41.00 16,984
29th Jun 2026 (Mon) 41.00 41.00 41.00 41.00 33,929
26th Jun 2026 (Fri) 41.50 41.40 41.40 41.40 80,443
25th Jun 2026 (Thu) 42.00 42.00 41.50 41.50 71,578
24th Jun 2026 (Wed) 43.50 43.50 43.50 43.50 3,869
23rd Jun 2026 (Tue) 44.00 45.00 43.50 43.50 30,339
22nd Jun 2026 (Mon) 43.50 44.50 43.50 44.00 15,160
19th Jun 2026 (Fri) 43.50 43.50 43.50 43.50 3,731
18th Jun 2026 (Thu) 42.50 44.50 42.60 43.50 201,046
17th Jun 2026 (Wed) 42.50 42.50 40.60 42.50 56,567
16th Jun 2026 (Tue) 45.00 42.00 42.00 42.00 198,831
15th Jun 2026 (Mon) 45.00 45.50 42.80 45.00 231,618
12th Jun 2026 (Fri) 43.50 45.00 43.50 45.00 17,943
11th Jun 2026 (Thu) 43.50 43.50 43.50 43.50 6,141
10th Jun 2026 (Wed) 43.50 43.50 43.50 43.50 43,256
See more Faron Pharmaceuticals price history

Faron Pharmaceuticals (FARN) Share News

IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki

5th Jun 2026 12:37

Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,000 fine over breaches in 2024. The committee found that Faron breached the Nasdaq First North Growth Rulebook for Issuers of Shares, regarding "the obligation to disclose inside information without undue delay in certain matters". It also breached "good securities market practise" regarding "certain public statements made in a media interview". Faron notes that the committee dismissed two alleged breaches, including "importantly," the allegation that Faron had not organised its administration in the manner required for listed companies. Read More

UK shareholder meetings calendar - next 7 days

27th Apr 2026 12:17

Read More

WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake

14th Apr 2026 11:37

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday. Read More

WINNERS & LOSERS: Secure Trust holds provision; Steppe sales rise

10th Apr 2026 10:11

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Friday. Read More

IN BRIEF: Faron Pharmaceuticals hires Heikki Jouttijarvi as CTO

27th Mar 2026 07:00

Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Hires Heikki Jouttijarvi as chief technical officer, saying he has decades of experience in biopharma manufacturing, supply chain management and commercial operations. Chief Executive Officer Juho Jalkanen says: "His wealth of experience with commercial operations, manufacturing and supply chain management with late-stage and approved drugs is incredibly valuable for us as we progress with bexmarilimab to the announced phase IIb trial in higher-risk myelodysplastic syndromes". Bexmarilimab is an investigational immunotherapy designed to overcome resistance to existing treatments, among others. Myelodysplastic syndromes are a type of blood cancer. Read More

See more Faron Pharmaceuticals news
FTSE 100 Latest
Value10,472.45
Change-16.59

Login to your account

Forgot Password?

Not Registered